Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 21, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2026

Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL

Gamma Delta T-Cell Infusion

Donor cells will be processed in a laboratory, where T-cell subtype called γδ (gamma delta) T-cells will be isolated and expanded in number. These T-cells expanded in a laboratory will be infused in participants who are otherwise at high risk of AML recurrence after alloHCT.

Trial Locations (1)

33612

Moffitt Cancer Center, Tampa

All Listed Sponsors
collaborator

Florida Department of Health

OTHER_GOV

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER